Interest of the Immunoscore® as a Post-operative Complementary Tool for the Detection of the Risk of Recurrence in Patients With Nonmetastatic Colorectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-04

Study Completion Date

2028-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the patient care recommandation induced by the IMMUNOSCORE® result

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer

NCT01688232

Colorectal Cancer Surgical Resection of the Colorectal Tumor

UNKNOWN

Personalized Medicine in Early Stage Colorectal Cancer: Organ Preservation and Immune Benefit

NCT06251726

Colorectal Cancer

NOT_YET_RECRUITING

Cohort Study to Evaluate the Relapse Risk Test in Colorectal Cancer

NCT05115786

Colorectal Cancer

UNKNOWN

Role of Immunoscore® in Stage II-III Colorectal Cancer

NCT05422547

Colon Adenocarcinoma

UNKNOWN

Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms

NCT05038358

Primary Tumor Colon Tumor

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Metastatic Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IMMUNOSCORE®

Group Type EXPERIMENTAL

IMMUNOSCORE®

Intervention Type DIAGNOSTIC_TEST

recommendation for patient care according to the result of the IMMUNOSCORE®

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IMMUNOSCORE®

recommendation for patient care according to the result of the IMMUNOSCORE®

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age between 18 and 80 inclusive;
* histologically confirmed colon adenocarcinoma;
* having undergone a curative resection of stage I, II or III colorectal cancer;
* diagnosed T1 / T2 / T3 / T4 and N0 / N1 / N2;
* eligible to receive 6 months of adjuvant chemotherapy;
* having given free, informed and written consent;
* agreeing to the use of a tumor sample for research purposes;
* being affiliated to a social security system.

Exclusion Criteria

* pregnant or breastfeeding women
* legal incapacity or physical, psychological, social or geographical conditions preventing the patient from signing the consent or completing the study.
* history of other solid tumor within 3 years before inclusion, with the exception of in-situ cancer of the cervix and skin cancers (basal or squamous) treated and controlled
* person subject to a safeguard measure.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No